New York State Common Retirement Fund’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $58.8K | Buy |
+44,900
| New | +$62K | ﹤0.01% | 2930 |
|
|
2025
Q2 | – | Sell |
-3,319
| Closed | -$1.5K | – | 3269 |
|
|
2025
Q1 | $1.5K | Hold |
3,319
| – | – | ﹤0.01% | 3161 |
|
|
2024
Q4 | $1.67K | Hold |
3,319
| – | – | ﹤0.01% | 3167 |
|
|
2024
Q3 | $3K | Hold |
3,319
| – | – | ﹤0.01% | 3158 |
|
|
2024
Q2 | $3.31K | Buy |
3,319
+27
| +0.8% | +$30 | ﹤0.01% | 3254 |
|
|
2024
Q1 | $4.87K | Buy |
3,292
+132
| +4% | +$150 | ﹤0.01% | 3216 |
|
|
2023
Q4 | $3.44K | Sell |
3,160
-395
| -11% | -$433 | ﹤0.01% | 3228 |
|
|
2023
Q3 | $4.2K | Sell |
3,555
-64,045
| -95% | -$87.1K | ﹤0.01% | 3241 |
|
|
2023
Q2 | $95.3K | Buy |
+67,600
| New | +$93.4K | ﹤0.01% | 2887 |
|
|
2022
Q3 | – | Sell |
-907
| Closed | -$1K | – | 3375 |
|
|
2022
Q2 | $1K | Sell |
907
-68,222
| -99% | -$90K | ﹤0.01% | 3371 |
|
|
2022
Q1 | $106K | Buy |
69,129
+207
| +0.3% | +$321 | ﹤0.01% | 3005 |
|
|
2021
Q4 | $169K | Sell |
68,922
-228
| -0.3% | -$534 | ﹤0.01% | 2929 |
|
|
2021
Q3 | $174K | Sell |
69,150
-34,750
| -33% | -$89.2K | ﹤0.01% | 2963 |
|
|
2021
Q2 | $296K | Buy |
+103,900
| New | +$269K | ﹤0.01% | 2855 |
|
|
2020
Q2 | – | Sell |
-69,500
| Closed | -$58K | – | 3249 |
|
|
2020
Q1 | $58K | Hold |
69,500
| – | – | ﹤0.01% | 2946 |
|
|
2019
Q4 | $62K | Hold |
69,500
| – | – | ﹤0.01% | 3099 |
|
|
2019
Q3 | $68K | Hold |
69,500
| – | – | ﹤0.01% | 3112 |
|
|
2019
Q2 | $76K | Hold |
69,500
| – | – | ﹤0.01% | 3165 |
|
|
2019
Q1 | $91K | Hold |
69,500
| – | – | ﹤0.01% | 2976 |
|
|
2018
Q4 | $63K | Sell |
69,500
-9,939
| -13% | -$15.2K | ﹤0.01% | 3062 |
|
|
2018
Q3 | $163K | Hold |
79,439
| – | – | ﹤0.01% | 2915 |
|
|
2018
Q2 | $143K | Hold |
79,439
| – | – | ﹤0.01% | 3008 |
|
|
2018
Q1 | $187K | Hold |
79,439
| – | – | ﹤0.01% | 2759 |
|
|
2017
Q4 | $149K | Hold |
79,439
| – | – | ﹤0.01% | 2878 |
|
|
2017
Q3 | $197K | Hold |
79,439
| – | – | ﹤0.01% | 2776 |
|
|
2017
Q2 | $219K | Sell |
79,439
-1
| -0% | -$3 | ﹤0.01% | 2803 |
|
|
2017
Q1 | $240K | Buy |
79,440
+25,147
| +46% | +$71.4K | ﹤0.01% | 2703 |
|
|
2016
Q4 | $171K | Hold |
54,293
| – | – | ﹤0.01% | 2824 |
|
|
2016
Q3 | $185K | Hold |
54,293
| – | – | ﹤0.01% | 2783 |
|
|
2016
Q2 | $124K | Hold |
54,293
| – | – | ﹤0.01% | 2917 |
|
|
2016
Q1 | $136K | Sell |
54,293
-4,560
| -8% | -$10.2K | ﹤0.01% | 2838 |
|
|
2015
Q4 | $195K | Hold |
58,853
| – | – | ﹤0.01% | 2786 |
|
|
2015
Q3 | $143K | Sell |
58,853
-9,814
| -14% | -$25.4K | ﹤0.01% | 2931 |
|
|
2015
Q2 | $201K | Buy |
+68,667
| New | +$266K | ﹤0.01% | 2917 |
|
Other funds holding LCTX
BC
DC
RA
New York State Common Retirement Fund's LCTX Position: Q2 2026 in Review
New York State Common Retirement Fund opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 44,900 shares worth $58.8K. The stake represents ﹤0.01% of the portfolio and ranks #2930 among its holdings. This is a return to the name: New York State Common Retirement Fund previously reported a position in LCTX as recently as Q1 2025.
New York State Common Retirement Fund first reported a position in LCTX in Q2 2015 and has held it in 34 quarters since. The position peaked at $296K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- New York State Common Retirement Fund held 44,900 shares of Lineage Cell Therapeutics worth $58.8K as of Q2 2026.
- Lineage Cell Therapeutics was a new New York State Common Retirement Fund position in Q2 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2930 holding.
- New York State Common Retirement Fund first reported a position in Lineage Cell Therapeutics in Q2 2015 and has held it in 34 quarters since.
- New York State Common Retirement Fund's Lineage Cell Therapeutics position peaked at $296K in Q2 2021.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.